2,6-Difluorobenzyl chloride

We are 2,6-Difluorobenzyl chloride CAS:697-73-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2,6-Difluorobenzyl chloride
CAS.NO:697-73-4
Synonyms:2,6-Difluorobenzyl chloride
2-(Chloromethyl)-1,3-difluorobenzene
α-Chloro-2,6-difluorotoluene
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Boiling Point 170.4±25.0 °C at 760 mmHg
Melting Point 34-38 °C(lit.)
Molecular Formula C7H5ClF2
Molecular Weight 162.564
Flash Point 59.5±16.6 °C
 
Specification:
Appearance:Light yellow transparent liquid or powder
Assay:≥98.0%
Sum of unknown impurities:≤2.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Rufinamide(CAS:106308-44-5).

2,6-Difluorobenzyl chloride


Related News: Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms.4,4,5,5-tetrametil-2- (3- (trifenil-2-il) fenil) -1,3,2-dioxaborolano CAS:1115639-92-3 The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.N-etil-2,3-dioxopiperazina CAS:59702-31-7 The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.124-68-5 The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.Ten domestic API leading enterprises of CSPC, Puluo Pharmaceutical, Huahai Pharmaceutical, Chuang Nuo Pharmaceutical, Federal Pharmaceuticals, Zhejiang Pharmaceutical, Yifan Pharmaceutical, Jiangxi Tianxin, Zhejiang Chemical Industry, and Xinhua Pharmaceutical rank among China’s API exporters The top ten in the list.

Related Products
Product Name
tetragastrin View Details
3-Bromo-2-Nitropyridine View Details
4-(Trans-4-pentylcyclohexyl) phenyl boronic acid View Details
3,4-Hexanedione manufacturer (7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate manufacturer 5-Bromo-2-fluoroaniline manufacturer 1-Methylimidazole manufacturer 3-Bromo-1-propanol manufacturer